OncoMatch/Clinical Trials/NCT06907615
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Is NCT06907615 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including HLX43 DOSE 1 (2.0 mg/kg) and HLX43 DOSE 2 (2.5 mg/kg) for non small cell lung cancer.
Treatment: HLX43 DOSE 1 (2.0 mg/kg) · HLX43 DOSE 2 (2.5 mg/kg) — The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: ALK wild-type
Required: BRAF wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Required: MET wild-type
Required: NTRK1 wild-type
Required: NTRK2 wild-type
Required: NTRK3 wild-type
Required: RET wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-(L)1 antibody
including at least anti-PD-(L)1 antibody
Must have received: platinum-based chemotherapy
including at least ... platinum-based chemotherapy
Cannot have received: topoisomerase I inhibitor
Prior treatment with any medication targeting topoisomerase I, including chemotherapy or ADCs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Hospital · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify